A more detailed model of the dynamics of the changes might have a small effect on the outcome, but not at a level that would make any difference in comparison with
the other uncertainties of the calculation.
Not exact matches
Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases in the build rates
of certain aircraft; 6) the effect on aircraft demand and build rates
of changing customer preferences for business aircraft, including the effect
of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result
of global economic
uncertainty or otherwise; 8) the effect
of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution
of key milestones such as the receipt
of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or
other third party approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our
other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and
other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production
of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts
of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak
of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or
other security attacks, information technology failures, or
other disruptions; 16) returns on pension plan assets and the impact
of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and
other aerostructures suppliers; 19) the effect
of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect
of changes in tax law, such as the effect
of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and
other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness
of any interest rate hedging programs; 28) the effectiveness
of our internal control over financial reporting; 29) the outcome or impact
of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and
other cost savings; 32) our ability to consummate our announced acquisition
of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and
other business disruptions for ourselves and Asco as a result
of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations in foreign current exchange rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among
other things.
In addition,
other risks and
uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy
of any such forward - looking statements.
And it's graded on a scale
of 0 to 600, based on the mention
of sets
of terms revolving around the economy,
uncertainty, Congress, legislation and regulation, among
others, culled from thousands
of newspapers around the country.
«You have more regulatory
uncertainty... and because
of these falls you have these
other outfalls,» he said, referring to the collapse
of some cryptocurrencies in the recent slump in prices.
These factors include, but are not limited to, the prospects
of entering into agreements with existing or
other carriers to fly new aircraft, ongoing negotiations between SkyWest, SkyWest Airlines and ExpressJet and their major partners regarding their contractual obligations,
uncertainties regarding operation
of new aircraft, the ability to attract and retain qualified pilots, the impact
of regulatory issues such as pilot rest rules and qualification requirements, and the ability to obtain aircraft financing.
The
uncertainty would cripple business confidence and trade, driving the UK into a recession, according to the International Monetary Fund, the Bank
of England and most every
other forecaster that has run the numbers.
«Most importantly it also removes
uncertainty and allows us to plan use
of our capital for
other priorities, especially pharmaceuticals R&D.»
Such factors include, among
others, general business, economic, competitive, political and social
uncertainties; the actual results
of current and future exploration activities; the actual results
of reclamation activities; conclusions
of economic evaluations; meeting various expected cost estimates; changes in project parameters and / or economic assessments as plans continue to be refined; future prices
of metals; possible variations
of mineral grade or recovery rates; the risk that actual costs may exceed estimated costs; failure
of plant, equipment or processes to operate as anticipated; accidents, labour disputes and
other risks
of the mining industry; political instability; delays in obtaining governmental approvals or financing or in the completion
of development or construction activities, as well as those factors discussed in the section entitled «Risk Factors» in the Company's Annual Information Form for the year ended December 31, 2017 dated March 15, 2018.
Forward - looking statements involve known and unknown risks,
uncertainties and
other factors which may cause the actual results, performance or achievements
of Dalradian to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements.
Certain matters discussed in this news release are forward - looking statements that involve a number
of risks and
uncertainties including, but not limited to, doubts about the Company's ability to continue as a going concern, the need to obtain additional funding, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance
of new products, the impact
of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights
of the Company and its competitors, risk
of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and
other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission.
These risks and
uncertainties include, among
others: the unfavorable outcome
of litigation, including so - called «Paragraph IV» litigation and
other patent litigation, related to any
of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components
of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence
of efficacy and adequacy
of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results
of our clinical development activities may not be positive, or predictive
of real - world results or
of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights
of third parties, or have unintended side effects, adverse reactions or incidents
of misuse; and those risks and
uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
«There is major
uncertainty in the market and federal agencies are not sure until the budget is passed and sequestration is resolved that they will continue, and they have really reduced the scale
of work,» says Zia Islam, founder
of Zantech IT Services, a McLean, Virginia - based company that has worked for NASA, the U.S. Department
of Housing and Urban Development, and
other federal agencies.
Other entrepreneurs from around the world are simply opting to start the company in Canada rather than the U.S. because
of all the
uncertainty around visa status.
However, managers often engage in herd behavior in the face
of uncertainty, and firms often end up imitating each
other.
While there is no lack
of political and economic
uncertainty in the U.S., volatility in the U.S. is modest compared to that
of other nations around the globe, says Mark Heesen, president
of the NVCA, in a statement.
Potential risks and
uncertainties include, among
others, the possibility that the anticipated synergies
of the combined companies may not be achieved after closing, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either company does business may deteriorate and / or Oracle or Vocado may be adversely affected by
other economic, business, and / or competitive factors.
Unstuck is there to help you resolve problems, find motivation or face
other moments
of paralyzing
uncertainty.
Further, PDC urges you to carefully review and consider the cautionary statements and disclosures, specifically those under the heading «Risk Factors,» made in its Quarterly Report on Form 10 - Q, its Annual Report on Form 10 - K for the year ended December 31, 2016 (the «2016 Form 10 - K»), filed with the U.S. Securities and Exchange Commission («SEC») on February 28, 2017 and amended on May 1, 2018, and
other filings with the SEC for further information on risks and
uncertainties that could affect the Company's business, financial condition, results
of operations, and prospects, which are incorporated by this reference as though fully set forth herein.
Lynne Doughtie, chairman and CEO
of KPMG in the U.S. told Fortune that — in talking to
other business leaders this week — she got the impression that they are encouraged with Trump's tax reforms, but «there's
uncertainty around trade.»
Actual results and the timing
of events could differ materially from those anticipated in the forward - looking statements due to these risks and
uncertainties as well as
other factors, which include, without limitation: the uncertain timing
of, and risks relating to, the executive search process; risks related to the potential failure
of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies
of eptinezumab sufficient to achieve a positive completion; the availability
of data at the expected times; the clinical, therapeutic and commercial value
of eptinezumab; risks and
uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and
uncertainties relating to the manufacture
of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights
of others; the uncertain timing and level
of expenses associated with Alder's development and commercialization activities; the sufficiency
of Alder's capital and
other resources; market competition; changes in economic and business conditions; and
other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.
Thus, the
other school
of thought says not to lay off salespeople during times
of uncertainty.
Such risks,
uncertainties and
other factors include, without limitation: (1) the effect
of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels
of end market demand in construction and in both the commercial and defense segments
of the aerospace industry, levels
of air travel, financial condition
of commercial airlines, the impact
of weather conditions and natural disasters and the financial condition
of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization
of the anticipated benefits
of advanced technologies and new products and services; (3) the scope, nature, impact or timing
of acquisition and divestiture or restructuring activity, including the pending acquisition
of Rockwell Collins, including among
other things integration
of acquired businesses into United Technologies» existing businesses and realization
of synergies and opportunities for growth and innovation; (4) future timing and levels
of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability
of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope
of future repurchases
of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level
of other investing activities and uses
of cash, including in connection with the proposed acquisition
of Rockwell; (7) delays and disruption in delivery
of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and
other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits
of organizational changes; (11) the anticipated benefits
of diversification and balance
of operations across product lines, regions and industries; (12) the outcome
of legal proceedings, investigations and
other contingencies; (13) pension plan assumptions and future contributions; (14) the impact
of the negotiation
of collective bargaining agreements and labor disputes; (15) the effect
of changes in political conditions in the U.S. and
other countries in which United Technologies and Rockwell Collins operate, including the effect
of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect
of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act
of 2017), environmental, regulatory (including among
other things import / export) and
other laws and regulations in the U.S. and
other countries in which United Technologies and Rockwell Collins operate; (17) the ability
of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition
of conditions that could adversely affect the combined company or the expected benefits
of the merger) and to satisfy the
other conditions to the closing
of the pending acquisition on a timely basis or at all; (18) the occurrence
of events that may give rise to a right
of one or both
of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee
of $ 695 million to United Technologies or $ 50 million
of expense reimbursement; (19) negative effects
of the announcement or the completion
of the merger on the market price
of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation
of their businesses while the merger agreement is in effect; (21) risks relating to the value
of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or
other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability
of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
Such forward - looking statements involve known and unknown risks,
uncertainties and
other important factors that could cause the actual results, performance or achievements
of SES to be materially different from future results, performance or achievements expressed or implied by such forward - looking statements.
To go it alone, on the
other hand, the inventor must undertake the cumbersome effort
of setting up a new firm and dealing with the
uncertainty that any new invention faces in the market.
Certain proposed transactions, including the divestiture
of Humana's subsidiary, KMG America Corporation, the acquisition
of a minority interest in Kindred Healthcare, Inc.'s Kindred at Home division by Humana, as well as the acquisition
of a minority interest in Curo Healthcare Services by Humana are subject to various closing conditions, including various regulatory approvals and customary closing conditions, as well as
other uncertainties, and there can be no assurances as to whether and when these transactions may be completed.
In
other words, does
UNCERTAINTY about forward movement in the administration's program start to affect the financial markets and the market's view
of the potential for reforms that have been a significant force in both the equity and bond markets since the election?
Despite this and
other authoritative warnings about the dangers
of climate change, Mr. Pruitt persists in pointing to
uncertainty about the precise extent
of humanity's contribution to the problem as a basis for resisting taking any regulatory action to help solve it.
The press release may, in some cases, use terms such as «predicts,» «believes,» «potential,» «proposed,» «continue,» «estimates,» «anticipates,» «expects,» «expected,» «plans,» «intends,» «may,» «could,» «might,» «will,» «should» or
other words that convey
uncertainty of future events or outcomes to identify these forward - looking statements.
«Our illustrative estimate
of the long term impact
of reduced net migration from the EU27 on UK GDP per capita after Brexit is negative, but relatively small compared to many
other uncertainties about average UK income levels in 2030,» said Hawksworth.
Actual results, including with respect to our targets and prospects, could differ materially due to a number
of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political
uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up
of production
of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception
of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall
of our products; ongoing
uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability
of receivables and
other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration
of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers
of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits
of the transaction; the risk that retail customers may alter promotional pricing, increase promotion
of a competitor's products over our products or reduce their inventory levels, all
of which could negatively affect product demand; the risk that our investments may experience periods
of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity
of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization
of products under development, such as our pipeline
of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development
of new technology and competing products that may impair demand or render our products obsolete; the potential lack
of customer acceptance for our products; risks associated with ongoing litigation; and
other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.
«Brexit would also hold back GDP in
other European economies, particularly in the near - term, resulting from (the) heightened
uncertainty (it) would create about the future
of Europe,» the report added.
This press release may, in some cases, use terms such as «predicts,» «believes,» «potential,» «proposed,» «continue,» «estimates,» «anticipates,» «expects,» «expected,» «plans,» «intends,» «may,» «could,» «might,» «will,» «should» or
other words that convey
uncertainty of future events or outcomes to identify these forward - looking statements.
But
uncertainty over the DOJ fine and the pending resolution
of other legacy issues has prevented the government from being able to begin selling its stake.
Facebook's decision to expand its British presence despite the looming
uncertainty of Brexit echoes that
of other tech giants such as Google and Amazon.
But in
other areas, like in entertainment or with start - ups, there's a higher level
of uncertainty.
Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among
others, the following: our ability to successfully and profitably market our products and services; the acceptance
of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness
of health insurance companies and
other payers to cover Cologuard and adequately reimburse us for our performance
of the Cologuard test; the amount and nature
of competition from
other cancer screening and diagnostic products and services; the effects
of the adoption, modification or repeal
of any healthcare reform law, rule, order, interpretation or policy; the effects
of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result
of the Protecting Access to Medicare Act
of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the
other risks and
uncertainties described in the Risk Factors and in Management's Discussion and Analysis
of Financial Condition and Results
of Operations sections
of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.
If Brexit - like sentiment in
other nations leads to restrictions on the flow
of trade and labor, he adds, «that is going to create greater
uncertainty and volatility» — at a time when some commentators believe that global stock and bond prices are overdue for a tumble.
Uncertainty about the economy and fiscal issues are expected to weigh on the franchise sector in 2013, but it is still expected to outpace
other industries in terms
of growth, according to the report.
Readers are cautioned that these forward - looking statements are only predictions and may differ materially from actual future events or results due a variety
of factors, including, among
other things, that conditions to the closing
of the transaction may not be satisfied, the potential impact on the business
of Accompany due to the
uncertainty about the acquisition, the retention
of employees
of Accompany and the ability
of Cisco to successfully integrate Accompany and to achieve expected benefits, business and economic conditions and growth trends in the networking industry, customer markets and various geographic regions, global economic conditions and
uncertainties in the geopolitical environment and
other risk factors set forth in Cisco's most recent reports on Form 10 - K and Form 10 - Q.
A further list and description
of these risks,
uncertainties and
other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10 - Q.
And the experience is almost worse if you try to make things interactive as a lack
of visual cues means people either talk over each
other or hold back out
of uncertainty, leaving gaping chasms
of silence.
It also shows that networking helps cofounders find each
other by removing some
of the
uncertainty around pairing up in advance, and that entrepreneurs use information gained during networking to find talented cofounders.
These risks and
uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and
other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or
other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over
other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or
other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and
other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
This should motivate greater attention to and study
of the consequences
of mini flash crashes, including the retroactive investigation into patterns
of mini flash crashes prior to
other flash crashes that are surrounded by great causal
uncertainty, such as the Flash Crash
of the U.S. Dollar on March 18, 2015 [25].
The possibility
of failed elections introduces unnecessary legal
uncertainty and risk to our director election process as vacancies on our board
of directors could result in our inability to comply with certain NASDAQ listing requirements or
other securities regulations.
These risks and
uncertainties include competition and
other economic conditions including fragmentation
of the media landscape and competition from
other media alternatives; changes in advertising demand, circulation levels and audience shares; the Company's ability to develop and grow its online businesses; the Company's reliance on revenue from printing and distributing third - party publications; changes in newsprint prices; macroeconomic trends and conditions; the Company's ability to adapt to technological changes; the Company's ability to realize benefits or synergies from acquisitions or divestitures or to operate its businesses effectively following acquisitions or divestitures; the Company's success in implementing expense mitigation efforts; the Company's reliance on third - party vendors for various services; adverse results from litigation, governmental investigations or tax - related proceedings or audits; the Company's ability to attract and retain employees; the Company's ability to satisfy pension and
other postretirement employee benefit obligations; changes in accounting standards; the effect
of labor strikes, lockouts and labor negotiations; regulatory and judicial rulings; the Company's indebtedness and ability to comply with debt covenants applicable to its debt facilities; the Company's ability to satisfy future capital and liquidity requirements; the Company's ability to access the credit and capital markets at the times and in the amounts needed and on acceptable terms; and
other events beyond the Company's control that may result in unexpected adverse operating results.
The general importance
of reducing causal
uncertainty surrounding
other historic flash crashes is similar to the importance
of reducing causal
uncertainty surrounding the October 2014 U.S. Treasury Bond Flash Crash: causal
uncertainty threatens to erode trust in markets and impedes action to prevent similar events from occurring in the future.
There are
other headwinds affecting the global markets: somewhat slower growth in China, declining commodity markets, the
uncertainties surrounding the coming end
of QE2, and more restrictive fiscal policies in many countries.
«While we are pleased the industry continues growing at faster rates than
other sectors
of the economy, we could be growing much faster, creating more new jobs and businesses, if Washington addressed the tax, spending and regulatory
uncertainty plaguing the small business community in a meaningful way,» said IFA President & CEO Steve Caldeira.